Programme · resources
How catalytic capital could be used
Plain-language planning for NWPharmaTech’s CHR-P programme — a proposed Phase 2B study in people at clinical high risk for psychosis (CHR-P). This page is informational. It is not an offer to invest, a prospectus, or open subscription.
Last reviewed: 26 September 2026
Conceptual animation. It does not depict real participants, investors, payments or outcomes.
What this page is
This page explains how a planning target of approximately US$10 million relates to the proposed Phase 2B CHR-P programme. You cannot invest, pay, subscribe, or connect a wallet on this website.
One programme
The public programme is the proposed Phase 2B working design (approximately 328 participants; four arms; about 12 weeks of treatment with further follow-up). Effectiveness in this population has not been established. Other research tracks, if any, are documented internally for diligence and are not part of this public summary.
What ~US$10M means
Approximately US$10 million is a planning target for catalytic programme funding for the proposed Phase 2B CHR-P programme.
- It is not money already raised
- It is not a validated vendor invoice or current CRO quote
- It is not a priced offer on this website
- It is not a claim that catalytic capital fully funds a complete Phase 2B trial
Planning objective through concrete activities
Illustrative. Subject to financing, approvals, and current cost discovery, catalytic capital at the planning-target scale could be directed toward activities such as:
| Cluster | Illustrative activities |
|---|---|
| Clinical preparation | Version-controlled synopsis path; ethics and regulatory readiness; operationalisation of eligibility and endpoints with the clinical team |
| Trial operations | CRO selection and start-up; monitoring and project management setup; data-management and PV plans |
| Product supply | IMP / CMC activities required for a start window; packaging / labelling path as applicable |
| Regulatory work | Filings and interactions required for start-up in applicable jurisdictions |
| Data analysis | Statistics and medical writing path as funded under the use-of-proceeds |
| Contingency | Holdback for wind-down, ethics close-out, and audit |
These are illustrative activity clusters, not a promise that every line is funded or that sites are contracted.
Next funded-milestone framing
Proposed · planning.
Catalytic preparation and start-up toward a proposed Phase 2B.
The remaining funding need to complete a full multiregional 328-participant run is to-be-established, and no figure is published here, pending a current Phase 2B RFQ and Board use-of-proceeds.
How spend would be controlled
We are evaluating a platform-supported route for eligible investors to help finance the CHR-P research programme, including a permissioned digital record of participation at closing where that proves feasible. If a platform path cannot meet legal, operational or investor-access requirements, a conventional private placement with a legal investor register remains the fallback. These are development objectives, not live offering terms. Neither path is available on this website: production investment, payment and token issuance remain inactive. Community updates and discussion are separate from any regulated investment process.
Raised capital, if any, would sit in a ring-fenced programme vehicle under bank / custody accounts with dual-control release against operational milestones — not efficacy claims. NWPharmaTech remains pharmaceutical sponsor. Details: How the funding model works.
What supporters would not get
- No NWPharmaTech parent equity in this mandate
- No ownership of the medicine, core IP, or patient data
- No medical / clinical voting
- No public retail token sale or DEX liquidity
- Following the programme as a community member is not an investment entitlement
Next steps for visitors
Learn about the science · read the public synopsis · read How the funding model works · contact us about research or collaboration.
For a visual overview of the proposed structure, see Digital programme finance.
Express interest in programme financing
You cannot invest, pay, or connect a wallet on our website.
Exploratory and non-binding. This page is not an offer and does not reserve an allocation.
Register for programme updates — programme news only, and not required for a financing enquiry.